Business · Companies · 5 hrs ago
Russian regulator orders Grotex to pay 2bn rubles over patent violation
Russia’s antitrust regulator ordered drugmaker Grotex to pay 2 billion rubles to the federal budget, saying the money was illegally earned.
The regulator said Grotex broke competition law by selling Emforix, a generic medicine for type 2 diabetes, before the patent on the original drug expired.
It also said Grotex did not get the patent holder’s consent.
The patent covers empagliflozin, the medicine’s active ingredient, and is due to expire in November 2029.
The case began after a complaint from Boehringer Ingelheim and a representative of the patent holder.
Grotex must stop the violation and transfer the money to the federal budget, as the regulator ordered.
Russia’s Federal Antimonopoly Service ordered pharmaceutical company Grotex to pay 2 billion rubles into the federal budget.
The regulator said the money was income obtained illegally through a competition law violation.
It said Grotex had marketed the diabetes drug Emforix before the patent on the original drug expired.
The regulator said Grotex did not obtain the patent holder’s consent.
The patent on the active ingredient empagliflozin expires in November 2029.
- Who
- Russia’s Federal Antimonopoly Service ordered pharmaceutical company Grotex to make the payment.
- What
- Grotex was ordered to pay 2 billion rubles into the federal budget over a competition law violation.
- When
- The report was published on November 19, 2026. The regulator opened a case on August 19.
- Where
- Russia.
- Why
- The regulator said Grotex marketed Emforix before the patent on the original drug expired and without the patent holder’s consent.
This story does not have two clearly opposing sides.
The Federal Antimonopoly Service opened a case against Grotex over its marketing of generic Emforix before the original drug’s patent expired.
The regulator ordered Grotex to transfer 2 billion rubles into the federal budget.
- Payment ordered
- 2 billion rubles
- Company
- Grotex
- Drug
- Emforix, used against type 2 diabetes
- Active ingredient
- Empagliflozin
- Patent expiry
- November 2029
What people are saying
The Federal Antimonopoly Service of Russia recognized the pharmaceutical company as having violated the Law on Protection of Competition and issued a binding order to stop the violation and transfer to the federal budget illegally obtained income of 2 billion rubles.